Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1962 1
1963 1
1964 4
1965 1
1966 1
1967 3
1968 1
1970 1
1971 5
1972 4
1973 4
1974 6
1975 6
1976 6
1977 5
1978 8
1979 2
1980 3
1981 5
1982 5
1983 5
1984 7
1985 6
1986 3
1987 12
1988 10
1989 7
1990 11
1991 13
1992 8
1993 6
1994 8
1995 3
1996 6
1997 11
1998 13
1999 8
2000 13
2001 7
2002 14
2003 8
2004 19
2005 13
2006 11
2007 10
2008 17
2009 7
2010 4
2011 5
2012 6
2013 3
2014 6
2015 4
2016 6
2017 1
2018 5
2019 4
2020 9
2021 9
2022 4
2023 5
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

396 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Palatini P, Julius S, Zanchetti A. Palatini P, et al. Among authors: julius s. J Hypertens. 2016 Oct;34(10):2103-4. doi: 10.1097/HJH.0000000000001055. J Hypertens. 2016. PMID: 27579707 No abstract available.
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2021 Sep 18;398(10305):1053-1064. doi: 10.1016/S0140-6736(21)01921-8. Epub 2021 Aug 27. Lancet. 2021. PMID: 34461040 Free PMC article.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Among authors: julius s. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.
Borderline hypertension.
Julius S. Julius S. Clin Exp Hypertens. 1999 Jul-Aug;21(5-6):741-7. doi: 10.3109/10641969909061004. Clin Exp Hypertens. 1999. PMID: 10423097 Review.
Heart rate and the cardiovascular risk.
Palatini P, Julius S. Palatini P, et al. Among authors: julius s. J Hypertens. 1997 Jan;15(1):3-17. doi: 10.1097/00004872-199715010-00001. J Hypertens. 1997. PMID: 9050965 Review. No abstract available.
Of rat and man.
Julius S. Julius S. J Hypertens. 2003 Apr;21(4):705-6. doi: 10.1097/00004872-200304000-00012. J Hypertens. 2003. PMID: 12658015 Review. No abstract available.
396 results